122 related articles for article (PubMed ID: 32297747)
1. Structure-Activity Relationship of SPOP Inhibitors against Kidney Cancer.
Dong Z; Wang Z; Guo ZQ; Gong S; Zhang T; Liu J; Luo C; Jiang H; Yang CG
J Med Chem; 2020 May; 63(9):4849-4866. PubMed ID: 32297747
[TBL] [Abstract][Full Text] [Related]
2. Small-Molecule Targeting of E3 Ligase Adaptor SPOP in Kidney Cancer.
Guo ZQ; Zheng T; Chen B; Luo C; Ouyang S; Gong S; Li J; Mao LL; Lian F; Yang Y; Huang Y; Li L; Lu J; Zhang B; Zhou L; Ding H; Gao Z; Zhou L; Li G; Zhou R; Chen K; Liu J; Wen Y; Gong L; Ke Y; Yang SD; Qiu XB; Zhang N; Ren J; Zhong D; Yang CG; Liu J; Jiang H
Cancer Cell; 2016 Sep; 30(3):474-484. PubMed ID: 27622336
[TBL] [Abstract][Full Text] [Related]
3. The emerging role of SPOP protein in tumorigenesis and cancer therapy.
Song Y; Xu Y; Pan C; Yan L; Wang ZW; Zhu X
Mol Cancer; 2020 Jan; 19(1):2. PubMed ID: 31901237
[TBL] [Abstract][Full Text] [Related]
4. SPOP promotes ubiquitination and degradation of LATS1 to enhance kidney cancer progression.
Wang L; Lin M; Chu M; Liu Y; Ma J; He Y; Wang ZW
EBioMedicine; 2020 Jun; 56():102795. PubMed ID: 32460168
[TBL] [Abstract][Full Text] [Related]
5. Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation.
Zhang P; Wang D; Zhao Y; Ren S; Gao K; Ye Z; Wang S; Pan CW; Zhu Y; Yan Y; Yang Y; Wu D; He Y; Zhang J; Lu D; Liu X; Yu L; Zhao S; Li Y; Lin D; Wang Y; Wang L; Chen Y; Sun Y; Wang C; Huang H
Nat Med; 2017 Sep; 23(9):1055-1062. PubMed ID: 28805822
[TBL] [Abstract][Full Text] [Related]
6. SPOP-PTEN-SUFU axis promotes progression of clear cell renal cell carcinoma via activating SHH and WNT pathway.
Han B; Sun Z; Yu T; Wang Y; Kuang L; Li T; Cai J; Cao Q; Xu Y; Gao B; Cheng SY; Yue S; Liu C
Cell Death Discov; 2021 May; 7(1):120. PubMed ID: 34021128
[TBL] [Abstract][Full Text] [Related]
7. SPOP promotes tumorigenesis by acting as a key regulatory hub in kidney cancer.
Li G; Ci W; Karmakar S; Chen K; Dhar R; Fan Z; Guo Z; Zhang J; Ke Y; Wang L; Zhuang M; Hu S; Li X; Zhou L; Li X; Calabrese MF; Watson ER; Prasad SM; Rinker-Schaeffer C; Eggener SE; Stricker T; Tian Y; Schulman BA; Liu J; White KP
Cancer Cell; 2014 Apr; 25(4):455-68. PubMed ID: 24656772
[TBL] [Abstract][Full Text] [Related]
8. The diverse roles of SPOP in prostate cancer and kidney cancer.
Wang Z; Song Y; Ye M; Dai X; Zhu X; Wei W
Nat Rev Urol; 2020 Jun; 17(6):339-350. PubMed ID: 32355326
[TBL] [Abstract][Full Text] [Related]
9. Discovery and optimization of new benzimidazole- and benzoxazole-pyrimidone selective PI3Kβ inhibitors for the treatment of phosphatase and TENsin homologue (PTEN)-deficient cancers.
Certal V; Halley F; Virone-Oddos A; Delorme C; Karlsson A; Rak A; Thompson F; Filoche-Rommé B; El-Ahmad Y; Carry JC; Abecassis PY; Lejeune P; Vincent L; Bonnevaux H; Nicolas JP; Bertrand T; Marquette JP; Michot N; Benard T; Below P; Vade I; Chatreaux F; Lebourg G; Pilorge F; Angouillant-Boniface O; Louboutin A; Lengauer C; Schio L
J Med Chem; 2012 May; 55(10):4788-805. PubMed ID: 22524426
[TBL] [Abstract][Full Text] [Related]
10. Prostate cancer-associated mutation in SPOP impairs its ability to target Cdc20 for poly-ubiquitination and degradation.
Wu F; Dai X; Gan W; Wan L; Li M; Mitsiades N; Wei W; Ding Q; Zhang J
Cancer Lett; 2017 Jan; 385():207-214. PubMed ID: 27780719
[TBL] [Abstract][Full Text] [Related]
11. SPOP promotes SIRT2 degradation and suppresses non-small cell lung cancer cell growth.
Luo J; Bao YC; Ji XX; Chen B; Deng QF; Zhou SW
Biochem Biophys Res Commun; 2017 Feb; 483(2):880-884. PubMed ID: 28073696
[TBL] [Abstract][Full Text] [Related]
12. Dual inhibition of AKT-mTOR and AR signaling by targeting HDAC3 in
Yan Y; An J; Yang Y; Wu D; Bai Y; Cao W; Ma L; Chen J; Yu Z; He Y; Jin X; Pan Y; Ma T; Wang S; Hou X; Weroha SJ; Karnes RJ; Zhang J; Westendorf JJ; Wang L; Chen Y; Xu W; Zhu R; Wang D; Huang H
EMBO Mol Med; 2018 Apr; 10(4):. PubMed ID: 29523594
[TBL] [Abstract][Full Text] [Related]
13. Speckle-type POZ protein suppresses hepatocellular carcinoma cell migration and invasion via ubiquitin-dependent proteolysis of SUMO1/sentrin specific peptidase 7.
Ji P; Liang S; Li P; Xie C; Li J; Zhang K; Zheng X; Feng M; Li Q; Jiao H; Chi X; Zhao W; Zhang S; Wang X
Biochem Biophys Res Commun; 2018 Jul; 502(1):30-42. PubMed ID: 29777712
[TBL] [Abstract][Full Text] [Related]
14. Speckle-type POZ protein, SPOP, is involved in the DNA damage response.
Zhang D; Wang H; Sun M; Yang J; Zhang W; Han S; Xu B
Carcinogenesis; 2014 Aug; 35(8):1691-7. PubMed ID: 24451148
[TBL] [Abstract][Full Text] [Related]
15. SPOP regulates prostate epithelial cell proliferation and promotes ubiquitination and turnover of c-MYC oncoprotein.
Geng C; Kaochar S; Li M; Rajapakshe K; Fiskus W; Dong J; Foley C; Dong B; Zhang L; Kwon OJ; Shah SS; Bolaki M; Xin L; Ittmann M; O'Malley BW; Coarfa C; Mitsiades N
Oncogene; 2017 Aug; 36(33):4767-4777. PubMed ID: 28414305
[TBL] [Abstract][Full Text] [Related]
16. SPOP suppresses osteosarcoma invasion via PI3K/AKT/NF-κB signaling pathway.
Chen L; Pei H; Lu SJ; Liu ZJ; Yan L; Zhao XM; Hu B; Lu HG
Eur Rev Med Pharmacol Sci; 2018 Feb; 22(3):609-615. PubMed ID: 29461588
[TBL] [Abstract][Full Text] [Related]
17. NOTCH1 functions as an oncogene by regulating the PTEN/PI3K/AKT pathway in clear cell renal cell carcinoma.
Liu S; Ma X; Ai Q; Huang Q; Shi T; Zhu M; Wang B; Zhang X
Urol Oncol; 2013 Aug; 31(6):938-48. PubMed ID: 21993533
[TBL] [Abstract][Full Text] [Related]
18. Structure-based design and discovery of potent and selective KDM5 inhibitors.
Nie Z; Shi L; Lai C; O'Connell SM; Xu J; Stansfield RK; Hosfield DJ; Veal JM; Stafford JA
Bioorg Med Chem Lett; 2018 May; 28(9):1490-1494. PubMed ID: 29627262
[TBL] [Abstract][Full Text] [Related]
19. Speckle-type POZ protein suppresses lipid accumulation and prostate cancer growth by stabilizing fatty acid synthase.
Gang X; Xuan L; Zhao X; Lv Y; Li F; Wang Y; Wang G
Prostate; 2019 Jun; 79(8):864-871. PubMed ID: 30955223
[TBL] [Abstract][Full Text] [Related]
20. The association of speckle-type POZ protein with lymph node metastasis and prognosis in cancer patients: A meta-analysis.
Cheng F; Zeng C; Zeng L; Wu C; Chen Y
Medicine (Baltimore); 2019 Oct; 98(40):e17439. PubMed ID: 31577764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]